scored tablet

Prospective, randomized, double-blind, placebo-controlled, single-center comparative trial evaluating oral Istradefylline 40 mg once daily for reducing microglial activation in the brain of patients with progressive multiple sclerosis (MS)

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)